Study Results from French National Institute of Health and Medical Research (INSERM) in the Area of Health Insurance Reported (Prescription drug use…

Study Results from French National Institute of Health and Medical Research (INSERM) in the Area of Health Insurance Reported (Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample)

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- Investigators publish new report on Health Insurance. According to news reporting from Villejuif, France, by NewsRx journalists, research stated, "To provide an up-to-date account of drug prescription during pregnancy in France from 2011 to 2014 using the permanent sample of the French national computerized healthcare database and with a focus on recommended supplementations, fetotoxic drugs and teratogenic drugs. All pregnancies identified by the International Classification of Diseases, 10th Revision codes list in the hospitalization database, lasting more than 9?weeks of amenorrhea and whose delivery occurred between 01/01/2011 and 12/31/2014, were included."

The news correspondents obtained a quote from the research from the French National Institute of Health and Medical Research (INSERM), "Drugs delivered between the trimester before and until the end of the pregnancy were included. Drug exposure prevalence was calculated for each year and according to pregnancy trimesters. The study included 28,491 pregnancies with a median number of 9 [5-13] (median [IQ range]) drugs delivered. The most prescribed drug class was antianemia (in 72.5% of exposed). The prescription rate of recommended vitamins (B9 and D) increased over the study period (+10%). Influenza vaccination also increased but remained at a low rate (1%). Exposure to fetotoxic drugs decreased as pregnancy advanced. Exposure to the main teratogenic antiepileptics was stable over the study period. Low-income pregnant women had a higher average drug consumption except for recommended vitamins. Pregnant French women are among the largest consumers of prescription medications worldwide. Overall, the dispensation trends observed in this study are in line with the recommendations of the French National College of Gynecologists and Obstetricians. Nevertheless, while being low, exposure to fetotoxic drugs, teratogenic drugs or those under safety alerts still occurred."

According to the news reporters, the research concluded: "Supplementations and vaccines in low-income pregnant women should also be increased."

For more information on this research see: Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample. Pharmacoepidemiology and Drug Safety, 2017;():. (Wiley-Blackwell - www.wiley.com/; Pharmacoepidemiology and Drug Safety - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-1557)

Our news journalists report that additional information may be obtained by contacting R. Demailly, Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), INSERM, UVSQ, Institut Pasteur, Universite Paris-Saclay, Villejuif, France. Additional authors for this research include S. Escolano, C. Quantin, P. Tubert-Bitter and I. Ahmed (see also Health Insurance).

Keywords for this news article include: France, Europe, Villejuif, Epidemiology, Health Insurance, Drugs and Therapies, Insurance Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC